FORTUNE 500

			Revenues		Profits
Rank	Company	Fortune 500 rank	$ millions	% change from 2010	$ millions	% change from 2010
1	Pfizer	40	67,932.0	0.2	10,009.0	21.2
2	Johnson & Johnson	42	65,030.0	5.6	9,672.0	-27.5
3	Merck	57	48,047.0	4.5	6,272.0	628.5
4	Abbott Laboratories	71	38,851.3	10.5	4,728.4	2.2
5	Eli Lilly	119	24,286.5	5.2	4,347.7	-14.2
6	Bristol-Myers Squibb	134	21,244.0	9.0	3,709.0	19.6
7	Amgen	168	15,582.0	3.5	3,683.0	-20.4
8	Gilead Sciences	306	8,385.4	5.5	2,803.6	-3.4
9	Mylan	396	6,129.8	12.5	536.8	55.5
10	Allergan	448	5,419.1	10.2	934.5	155650.0
11	Biogen Idec	476	5,048.6	7.0	1,234.4	22.8
12	Celgene	492	4,842.1	33.5	1,318.2	49.7

Rank	Company	Revenues %	Assets %	Stockholders' Equity %
1	Pfizer	14.7	5.3	12.2
2	Johnson & Johnson	14.9	8.5	16.9
3	Merck	13.1	6.0	11.5
4	Abbott Laboratories	12.2	7.8	19.3
5	Eli Lilly	17.9	12.9	32.1
6	Bristol-Myers Squibb	17.5	11.2	23.2
7	Amgen	23.6	7.5	19.4
8	Gilead Sciences	33.4	16.2	41.6
9	Mylan	8.8	4.6	15.4
10	Allergan	17.2	11.0	17.6
11	Biogen Idec	24.5	13.6	19.2
12	Celgene	27.2	13.2	23.9

		Earnings Per Share	Total Return to Investors		Employees
Rank	Company	2001-2011 Annual growth (%)	2001-2011 Annual rate (%)	2011 (%)	Number	% change from 2010
1	Pfizer	0.4	-2.3	28.7	103,700	-6.2
2	Johnson & Johnson	6.6	3.6	9.9	117,900	3.4
3	Merck	-4.3	0.0	9.3	86,000	-8.5
4	Abbott Laboratories	11.8	3.5	21.7	91,922	0.5
5	Eli Lilly	4.3	-2.7	25.1	38,080	-0.7
6	Bristol-Myers Squibb	-1.3	1.0	39.4	27,000	0.0
7	Amgen	14.6	1.4	18.1	17,800	3.2
8	Gilead Sciences	49.2	17.4	12.9	4,500	12.5
9	Mylan	25.2	3.0	1.6	14,252	9.6
10	Allergan	13.6	9.7	28.1	10,000	8.7
11	Biogen Idec	23.9	4.8	64.1	5,011	3.3
12	Celgene	N.A.	23.8	14.3	4,460	6.6